Neurofibromatosis 1 Clinical Trial
Official title:
Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1
The purpose of this study is to find blood plasma based biomarkers of disease progression in neurofibromatosis type 1 (NF1). NF1 is associated with the development of benign cutaneous tumors as well as a variety of malignancies. Analysis of plasma DNA and chemical composition may provide tools for diagnosis and follow-up of NF1. The hypothesis of the study is that NF1-associated tumor burden and malignant transformation of tumors can be detected in plasma. To test this hypothesis, Finnish patients with NF1 are recruited and blood sample is taken. Blood plasma is separated and analyzed chemically. DNA is then also extracted and quantified.
Neurofibromatosis type 1 (NF1) is a dominant hereditary multiorgan disease that causes both benign cutaneous neurofibromas and malignant tumors. Timely detection of malignant transformation in NF1 tumors is of great clinical importance. Also methods to easily monitor individual's overall tumor burden would be useful. Blood plasma is collected from NF1 patients and age- and gender-matched controls. The samples are stored at -80 C until analysis. Free circulating plasma DNA is extracted and quantified using commercial reagents. Also a previously described chemical detection method to observe overall changes in plasma composition is utilized. The analysis results are compared between NF1 patients and healthy controls, and also correlated with NF1 tumor burden and diagnosis of malignancy during five-year follow-up. ;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00352599 -
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
|
Phase 1 | |
| Completed |
NCT05005845 -
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
|
Phase 2 | |
| Completed |
NCT03531814 -
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
|
N/A | |
| Completed |
NCT00846430 -
Medical Treatment of "High-Risk" Neurofibromas
|
Phase 2 | |
| Completed |
NCT03433183 -
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
Phase 2 | |
| Recruiting |
NCT05331105 -
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
|
Phase 2 | |
| Completed |
NCT03310996 -
Non-invasive Stimulation in Neurofibromatosis Type 1
|
N/A | |
| Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
| Recruiting |
NCT04750928 -
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06262113 -
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
|
N/A | |
| Active, not recruiting |
NCT04924608 -
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
|
Phase 3 | |
| Recruiting |
NCT02544022 -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
|
||
| Recruiting |
NCT04941027 -
Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
|
||
| Completed |
NCT02153931 -
Internet Support Group for Parents of a Child With Neurofibromatosis Type 1
|
||
| Completed |
NCT05196854 -
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1
|
N/A | |
| Active, not recruiting |
NCT01650142 -
Modifying Genes in Neurofibromatosis 1
|
N/A | |
| Completed |
NCT05377008 -
Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
|
N/A | |
| Completed |
NCT04879160 -
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
|
||
| Recruiting |
NCT05735717 -
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
|
Phase 2 |